Ceftriaxone

• UNSPSC Description:

  Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis[1][2][3][4][5][6][7].

• Target Antigen:

  Antibiotic; Aurora Kinase; Bacterial; GSK-3

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Cell Cycle/DNA Damage;Epigenetics;PI3K/Akt/mTOR;Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/ceftriaxone.html

• Purity:

  99.07

• Solubility:

  DMSO : 31.25 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(C(N12)=C(CSC(N(C)NC3=O)=NC3=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O

• Molecular Weight:

  554.58

• References & Citations:

  [1]Nahata MC, et al. Ceftriaxone: a third-generation cephalosporin. Drug Intell Clin Pharm. 1985 Dec;19(12):900-6.|[2] Nassar H, et al. Molecular docking, molecular dynamics simulations and in vitro screening reveal cefixime and ceftriaxone as GSK3β covalent inhibitors. RSC Adv. 2023 Apr 11;13(17):11278-11290.|[3]Zhang Y, et al. Ceftriaxone Protects Astrocytes from MPP(+) via Suppression of NF-κB/JNK/c-Jun Signaling. Mol Neurobiol. 2015 Aug;52(1):78-92.|[4]Li X, et al. Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B. Carcinogenesis. 2012 Dec;33(12):2548-57.|[5]Hakimizadeh E, et al. Ceftriaxone improves hepatorenal damages in mice subjected to D-galactose-induced aging. Life Sci. 2020 Oct 1;258:118119.|[6]Uyanikgil Y, et al. Positive effects of ceftriaxone on pentylenetetrazol-induced convulsion model in rats. Int J Neurosci. 2016;126(1):70-5.|[7]Gunduz O, et al. Anti-allodynic and anti-hyperalgesic effects of ceftriaxone in streptozocin-induced diabetic rats. Neurosci Lett. 2011 Mar 10;491(1):23-5.EBioMedicine. 2022 Apr;78:103943.|Cell Chem Biol. 2024 May 20:S2451-9456(24)00179-X.|Chemosphere. 2023 Oct 3:344:140353.|Emerg Microbes Infect. 2024 Dec;13(1):2321981.|Nat Commun. 2022 Mar 2;13(1):1116.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  73384-59-5